JX11502MA

JX11502MA is a novel small molecule antipsychotic drug candidate developed for the treatment of schizophrenia. It acts as a potent partial agonist at dopamine D2 and D3 receptors, with preferential binding to the D3 receptor, and also modulates serotonin receptors including 5-HT1A and 5-HT2A. The compound is structurally related to cariprazine. Clinical studies have shown that JX11502MA is generally well tolerated in healthy subjects at single doses up to 3 mg, with common adverse events including somnolence, dizziness, nausea, vomiting, and hiccups. The drug has demonstrated rapid absorption and a long terminal half-life in pharmacokinetic studies. Its mechanism of action suggests potential efficacy in treating symptoms of schizophrenia by modulating dopaminergic and serotonergic neurotransmission[1][2][5][6].